Back to Stocks

UTHR

UNITED THERAPEUTICS Corp
7 filings tracked
healthcarebiotechnologyLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

United Therapeutics is positioning itself for a massive valuation re-rating as it nears a critical inflection point in its product lifecycle.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Beneath the surface of United Therapeutics' reported numbers lies a deteriorating operating foundation characterized by shrinking margins and mounting competitive pressure. Total revenue slipped 1.6% year-over-year, while cost of sales surged 45% to $133.4 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every UTHR filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in a high-stakes transition, balancing a fortress-like financial history against an uncertain regulatory and competitive future. The immediate financial impact is a mix of aggressive shareholder returns and transitional margin hits. While the $1.5 billion buyback signals management's confidence in the intrinsic value of the firm, it also occurs as the core treprostinil business faces its first real headwinds from both branded competitors and generic entrants. Ultimately, the investment thesis hinges on the binary outcomes of the ralinepag and Nebulized Tyvaso (IPF) filings. If these products secure FDA approval and favorable Medicare coverage, UTHR can pivot from a defensive posture to a high-growth trajectory. However, the combination of rising operational costs and a volatile legal environment means that any delay in these catalysts could lead to a rapid deterioration of the current valuation. Investors are essentially betting on the company's ability to execute a flawless commercial ramp while defending its intellectual property moat.

Selected Quarter

Core Takeaway

UTHR is trading off short-term margin stability and cash reserves for a massive bet on two late-stage pipeline catalysts (ralinepag and Nebulized Tyvaso for IPF) expected by late 2026.

Investor Lens

The trade-off is between the certainty of current cash flow/buybacks and the speculative but massive upside of the upcoming FDA approvals.

Watch Next

The sNDA submission for Nebulized Tyvaso (IPF) and the NDA for ralinepag, both targeted for end of summer 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%
bearishMay 6

Total revenues declined 1.6% year-over-year to $781.5 million.

earnings miss
20%
bearishMay 6

Cost of sales surged 45% YoY, driven by a $26.8M inventory reserve.

margin compression
60%
bullishMay 6

Executed a massive $1.5 billion accelerated share repurchase program.

buyback
90%
bullishMay 6

Successful Phase 3 data for ralinepag and Nebulized Tyvaso (IPF) supports near-term NDA/sNDA filings.

guidance raise
70%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing reveals a company in a high-stakes transition, balancing a fortress-like financial history against an uncertain regulatory and competitive future. The immediate financial impact is a mix of aggressive shareholder returns and transitional margin hits. While the $1.5 billion buyback signals management's confidence in the intrinsic value of the firm, it also occurs as the core treprostinil business faces its first real headwinds from both branded competitors and generic entrants. Ultimately, the investment thesis hinges on the binary outcomes of the ralinepag and Nebulized Tyvaso (IPF) filings. If these products secure FDA approval and favorable Medicare coverage, UTHR can pivot from a defensive posture to a high-growth trajectory. However, the combination of rising operational costs and a volatile legal environment means that any delay in these catalysts could lead to a rapid deterioration of the current valuation. Investors are essentially betting on the company's ability to execute a flawless commercial ramp while defending its intellectual property moat.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.